Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 186 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: hypofractionation Clear all
Completed Phase 3 Interventional

Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00062309
View directory record Official record
Conditions
Prostate Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 20, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

NCT02639026
View directory record Official record
Conditions
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions
Radiotherapy, MEDI4736, Tremelimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 20, 2026, 7:41 PM EDT
Active, not recruiting Phase 2 Interventional

Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk

NCT03819985
View directory record Official record
Conditions
Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions
Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

NCT00983268
View directory record Official record
Conditions
Pancreatic Cancer, Periampullary Adenocarcinoma
Interventions
capecitabine, vorinostat, Radiotherapy, Surgery to remove tumor
Drug · Radiation · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 20, 2026, 7:41 PM EDT
Active, not recruiting Phase 2 Interventional

Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer

NCT03624660
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
HR-A, HR-B
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Not listed Not applicable Interventional

Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)

NCT01295723
View directory record Official record
Conditions
Invasive Lobular and Ductal Carcinoma
Interventions
Hypofractionated Whole Breast Radiation Therapy, Intraoperative Electron Radiation Therapy
Radiation
Lead sponsor
St. Joseph Hospital of Orange
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 20, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes

NCT02700386
View directory record Official record
Conditions
Breast Cancer
Interventions
Adjuvant Hypofractionated Radiation
Combination Product
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Active, not recruiting Not applicable Interventional

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT01345851
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy
Radiation · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Not yet recruiting Phase 2 Interventional

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

NCT07732634
View directory record Official record
Conditions
Head and Neck Cancer, Head Cancer, Neck Cancer
Interventions
RiMO-301, Pembrolizumab, Radiation, Surgical resection
Drug · Radiation · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer

NCT01215500
View directory record Official record
Conditions
Tumor, Cancer, Melanoma, Sarcoma, Carcinoma
Interventions
Hypofractionated RT
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 20, 2026, 7:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

NCT03414970
View directory record Official record
Conditions
Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions
Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy
Radiation · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
846
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Recruiting Not applicable Interventional

Pre-operative Hypofractionated Proton Therapy

NCT05917301
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
hypofractionation
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

NCT01230866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton Radiation Hypofractionation, Proton Radiation Standard Fractionation
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Warrenville, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Recruiting Phase 2 Interventional

Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma

NCT06905132
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM

NCT02202993
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM)
Interventions
Mibefradil with Radiation
Drug
Lead sponsor
Cavion, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 20, 2026, 7:41 PM EDT
Suspended Phase 1Phase 2 Interventional

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT04172532
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Duarte, California • Irvine, California • Orange, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Recruiting Phase 2 Interventional

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

NCT05038332
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ultra-hypofractionated radiation therapy, Moderately Hypo-fractionated Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Results available

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

NCT03801902
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy
Radiation · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
56
States / cities
Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 20, 2026, 7:41 PM EDT
Recruiting Phase 1 Interventional

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

NCT05136846
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy, Pemetrexed, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging of the Brain with and without Contrast, Biospecimen Collection
Drug · Biological · Radiation + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Duarte, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial

NCT05077735
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Hypofractionated Radiation Therapy, Questionnaire Administration, Magnetic Resonance Imaging, Computed Tomography Scan
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

NCT02968940
View directory record Official record
Conditions
Glioblastoma
Interventions
Avelumab, Hypofractionated radiation therapy (HFRT)
Biological · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 20, 2026, 7:41 PM EDT
Active, not recruiting Phase 2 Interventional

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

NCT03646617
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 7:41 PM EDT
Withdrawn Phase 2 Interventional

Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer

NCT03699033
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
2.5 Gy/fraction, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Stephanie Smiddy
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 20, 2026, 7:41 PM EDT
Recruiting Phase 2 Interventional

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

NCT07325721
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Interventions
Hypofractionated radiation with a microboost
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 7:41 PM EDT